JYJennifer H. Yang

Jennifer H. Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jennifer H. Yang has a total of 193 co-authors. Here are the top co-authors by number of shared publications:

  • Anastasie Dunn-Pirio

    From the Department of Neurosciences (J.H.Y., L.N., A.D.-P., J.S.G.), University of California, San Diego; Rady Children's Hospital San Diego (J.H.Y., L.N., J.S.G.); and School of Medicine (E.N.L.), University of California, San Diego

    3 shared publications
  • Jennifer S. Graves

    Department of Neurosciences, University of California San Diego, San Diego, CA, USA; Rady Children's Hospital San Diego, San Diego, CA, USA

    3 shared publications
  • Ashley Fair

    Boston University, Boston, MA, USA

    2 shared publications
  • Bruce H. Cohen

    Department of Pediatrics, Akron Children’s Hospital, Akron, USA

    2 shared publications
  • Denise Malicki

    Department of Pathology University of California San Diego San Diego California USA

    2 shared publications
  • Helen Harvey

    Division of Pediatrics University of California San Diego San Diego California USA

    2 shared publications

Latest Publications

  • Open Access

    Interim analysis of an international multi-site prospective natural history study evaluating the clinical presentation and progression of Leigh syndrome spectrum disorders

    by Laura E. MacMullen, Katelynn D. Stanley, John Christodoulou, Bruce H. Cohen, Matthew Demczko, Amy C. Goldstein, Richard Haas, Mary Kay Koenig, Maria Poblete, Alyssa Rice, et al.

    Background: Leigh Syndrome Spectrum (LSS) is the most common pediatric mitochondrial disease syndromic presentation. However, its natural history has not been well-characterized, particularly across diverse populations. Objectives: Information obtained through robust, prospective natural history studies (NHSs) in LSS will be foundational to accurately counsel newly diagnosed families, develop effective therapeutics, and identify outcome measures for future clinical trials. Design: We describe an ongoing multi-site, international, patient advocacy group funded, observational NHS in LSS. We employed a multi-site international federated design with local regulatory review coupled with central regulatory and coordinator support. To date, NHS outcome measures have been collected on LSS participants across 5 sites every 3 to 6 months for up to 3.8 years. Methods: Objective and subjective outcome measures were carefully selected by the international LSS outcome measure working group. Study data across sites were anonymized and combined for cleaning and analysis at the Data Coordinating Center (Children’s Hospital of Philadelphia). Descriptive statistics of the study cohort and inter-measure correlations were analyzed across NHS assessments. Results: Preliminary analysis of the first 74 participants was completed to characterize demographics, symptomatology, and clinical history. The average age at enrollment was 10.7 years, ranging from 0 to 50 years. The most common gene disorders were MT-ATP6 (22%, n=16), MT-ND5 (8%, n=6) and SURF1 (8%, n=6). No statistically significant between-group differences were detected by sex or genetic etiology. High inter-measure correlation between all the outcome measures and “gold standard” outcomes provides justification for future use of these assessments in both NHSs and clinical trials. Conclusion: We have demonstrated the feasibility of prospectively collecting robust international-site LSS NHS data through multi-site collaboration. These LSS community data will be critical for informing therapeutic development, outcome measure selection and clinical trial design, and providing baseline comparator evidence for development of future therapeutic interventions.

  • Open Access

    The clinical utility of functional testing in fibroblasts to diagnose primary mitochondrial disease

    by Johan L.K. Van Hove, Marisa W. Friederich, Roxanne A. Van Hove, Jessica C. Lee, Kaz M. Knight, Tonia E. Donovan, Lori Silveira, Rebecca D. Ganetzky, Michio Hirano, Jose Abdenur, et al.

    Genome sequencing of the heterogeneous primary mitochondrial disorders (PMD) frequently reveals variants of uncertain significance that require functional tests for diagnosis, and does not identify variants in all patients. We analyzed mitochondrial enzyme assays, blue native polyacrylamide gel electrophoresis (BN-PAGE) with in-gel activity staining, complex I assembly blot, and select protein abundances in fibroblasts of a case series of 204 PMD patients divided into functional classes, in comparison to 51 controls and 53 differential diagnostic conditions. Overall, sensitivity and specificity for respiratory chain enzyme assays were 46% and 93% respectively, for BN-PAGE 40% and 98%, for complex I assembly assay 49% and 99%. The overall sensitivity of all tests was 76%, specificity 93%, with positive predictive value 96% and negative predictive value 67%. Categories with high sensitivity were isolated complex deficiencies, nuclear DNA-encoded mitochondrial protein synthesis defects, co-factor defects, and mitochondrial amino-acyl-tRNA synthetase conditions when aided by protein abundance. Mitochondrial DNA mutations and maintenance disorders showed poor sensitivities. Secondary dysfunctions were rare. A complete battery of functional tests showed strong diagnostic clinical utility in fibroblasts. One sentence summary: A combination of four mitochondrial functional tests to identify or confirm suspected primary mitochondrial disease in fibroblasts had good sensitivity and excellent specificity, well beyond what was perceived using enzyme assays only.


  • Open Access

    Epigenetic age and telomere length correlations in pediatric-onset multiple sclerosis

    by Jennifer H Yang, Jonathan Race, Paige Sumowski, Kayla Jacques, Soha Fardad, Ashley Fair, Allison Hazlett, Jue Lin, Defne Yilmaz, Gregory Aaen, et al.

    Background: Age is the strongest factor determining disease expression in multiple sclerosis (MS). We previously demonstrated biological age acceleration in pediatric-onset MS (POMS) compared to controls with both epigenetic clocks (DNAm) and telomere length (TL). It is unknown whether these markers report overlapping or distinct aging-related processes. Objectives: To determine the correlation between DNAm and TL aging markers. Methods: We conducted a cross-sectional case–control study within the US Network of Pediatric MS Centers. We calculated age acceleration residuals for the Horvath, Hannum, PhenoAge, and GrimAge epigenetic clocks and measured TL from whole blood samples to estimate telomere to somatic DNA ratios (T/S ratio). We employed multivariable analysis of covariance to assess the correlation between DNAm estimates and TL. Results: We analyzed biological ages in 270 participants (125 POMS, mean 15.7 years; 145 controls, mean 15.3 years). There were moderate correlations among the different DNAm clocks, but no correlations between DNAm clocks and TL in pooled analyses. In a stratified analysis, only the control group showed a modest correlation between TL and PhenoAge clock ( r = 0.2, p = 0.06). Conclusions: DNAm did not correlate with TL in this sample of POMS and controls, suggesting that these biomarkers may capture complementary and non-overlapping elements of aging-related biology.


  • Open Access

    Racial and ethnic disparities in pediatric autoimmune encephalitis: A systematic review

    by Jennifer H. Yang, Kristen S. Fisher, Julia Dumcum, Sophie Zacharek, Alexandra B. Kornbluh, Kelsey Poisson, Mary C. Karalius, Leigh Sepeta


  • Isolated Psychiatric Symptoms in Children With Anti-N-Methyl-d Aspartate Receptor Encephalitis

    by Grace Gombolay, J. Nicholas Brenton, Jennifer H. Yang, Coral M. Stredny, Ryan Kammeyer, Kristen S. Fisher, Alexander J. Sandweiss, Timothy A. Erickson, Varun Kannan, Catherine Otten, et al.


  • Open Access

    Treatment Approaches in Pediatric Relapsing Autoimmune Encephalitis

    by Maayan J. Yakir, Jennifer H. Yang

    Purpose of review: Autoimmune encephalitis (AE) is increasingly recognized as a treatable cause of encephalitis in children. While prior observational studies demonstrate improved motor outcomes with early immunotherapy, less is known about long-term management and treatment for relapsing disease. In this review, we present current treatment approaches to pediatric AE, in particular relapse risk and treatment for relapsing AE in children. Recent findings: A recent meta-analysis of anti-NMDAR encephalitis demonstrated that disease onset in adolescence was associated with an increased odds of relapse whereas treatment with rituximab and IVIG for 6 months or longer were associated with a non-relapsing course. However, no specific pediatric sub-analyses were reported. A single-center study on adult and pediatric AE showed that rituximab use was associated with a reduction in time to relapse and recurring relapses although the data for the pediatric cohort did not achieve statistical significance. Summary: The use of second-line immunotherapy during the initial attack may reduce the risk for relapsing disease in pediatric AE. Larger studies are needed to investigate relapse risk and treatment in both anti-NMDAR and non-NMDAR encephalitis in children.


  • Open Access

    Senescence marker p16INK4a expression in patients with multiple sclerosis

    by Jennifer H. Yang, Annalise E. Miner, Ashley Fair, Revere Kinkel, Jennifer S. Graves


  • Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis

    by Jennifer H. Yang, Emilie N. Liu, Linda Nguyen, Anastasie Dunn-Pirio, Jennifer S. Graves

    Background and Objectives: Prior observational studies for autoimmune encephalitis (AE) have mostly focused on outcomes following acute immunotherapies with better outcomes associated with earlier immunotherapy use. However, the impact of long-term immunotherapy and its association with clinical relapse is not well known. Methods: We conducted a retrospective study of consecutive patients meeting published clinical criteria for AE evaluated at UC San Diego and Rady Children’s Hospital from January 2007 to November 2021. Survival analysis and Cox multivariable regression models were employed to evaluate relapse risk using rituximab exposure as a time-dependent variable. Pooled and age-stratified analyses were performed. Results: A total of 204 pediatric and 380 adult participants were screened of which 30 pediatric and 75 adult participants were included. The most common antibody subtype in both cohorts was anti-NMDA receptor (76% in pediatric, 34% in adult). Relapses occurred in 31% of pediatric antibody-positive, 40% of adult antibody-positive, and 20% of adult antibody-negative cases. Times to first relapse (TTFR) were 10.6 ± 7.4 months (pediatric antibody-positive), 13.1 ± 24.5 (adult antibody-positive) and 6.9 ± 3.8 months (adult antibody-negative). Rituximab was the most common second-line immunotherapy used. Combining pediatric and adult data, rituximab use was associated with a 71% lower hazard for time to first relapse (HR 0.29, 95% CI 0.09 – 0.85) and 51% lower hazard for recurring relapses (HR 0.49, 95% CI 0.9 – 1.26). The HR for TTFR with rituximab use in children was 0.30 (95% CI 0.05 – 1.69), 0.29 (95% CI 0.07 – 1.29) in adults, 0.32 in non-NMDA antibody-positive encephalitis (95% CI 0.07 – 1.39, and 0.42 (95% CI 0.07 – 2.67) for anti-NMDAR. Discussion: Relapses are common in pediatric and adult patients with AE, although less frequently in anti-NMDARE. Employing a rigorous survival model, we demonstrate a substantial benefit of rituximab use for reducing relapse rates in AE, especially for the adult population. Classification of Evidence: This study provides Class IV evidence that rituximab is associated with a lower hazard to relapse in patients with autoimmune encephalitis.


  • Open Access

    Refractory Status Epilepticus Associated With a Pathogenic Variant in TNFRSF13B

    by Jennifer H. Yang, Nicholas Scanlon, Wonhee Woo, Jamie N. LaBuzetta, Cynthia Gonzalez, Lori Broderick, Taylor Doherty, Marc Riedl, Anastasie Dunn-Pirio

    Febrile infection-related epilepsy syndrome (FIRES) is a rare epileptic syndrome characterized by new-onset refractory status epilepticus preceded by a febrile illness. Limited literature exists regarding the relationship between primary immunodeficiencies and immune-mediated epilepsy, and the relationship between new-onset refractory status epilepticus and common variable immunodeficiency (CVID) is not well-understood. We present a case of a 21-year-old female with a history of recurrent sinus infections, asthma, thrombocytopenia, atrioventricular nodal reentrant tachycardia, and neonatal seizures who presented with fever and new-onset status epilepticus. She was ultimately diagnosed with a heterozygous variant in TNFRSF13B c.311G>A (p.Cys104Tyr), which encodes for a tumor necrosis factor receptor implicated in CVID.


  • Top Cited Papers
    Open Access

    Therapeutic Advances in Multiple Sclerosis

    by Jennifer H. Yang, Torge Rempe, Natalie Whitmire, Anastasie Dunn-Pirio, Jennifer S. Graves

    Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that causes significant disability and healthcare burden. The treatment of MS has evolved over the past three decades with development of new, high efficacy disease modifying therapies targeting various mechanisms including immune modulation, immune cell suppression or depletion and enhanced immune cell sequestration. Emerging therapies include CNS-penetrant Bruton's tyrosine kinase inhibitors and autologous hematopoietic stem cell transplantation as well as therapies aimed at remyelination or neuroprotection. Therapy development for progressive MS has been more challenging with limited efficacy of current approved agents for inactive disease and older patients with MS. The aim of this review is to provide a broad overview of the current therapeutic landscape for MS.